Abbott (ABT), Reckitt Unit Defeat Infant-formula Sickness Claims - Bloomberg
Tweet
Share
E-mail
Get Alerts ABT Hot Sheet
Price: $88.18 -1.64%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +9.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +9.8%
Join SI Premium – FREE
Abbott (NYSE: ABT), Reckitt Unit Defeat Infant-formula Sickness Claims - Bloomberg
- Abbott, Reckitt Trial Victory Is First In Infant-formula Cases
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
- Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders
- Frequency Electronics secures $10 million credit facility with JPMorgan
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, LitigationRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
